WS016

Part A: Primary objective: To evaluate the efficacy and safety of different doses of WS016, administered orally once daily for 28 consecutive days, in subjects whose blood potassium reaches the target after the initial 2 days of hyperkalemia correction, to maintain blood potassium within the normal range (blood potassium: 3.5 – 5.0 mmol/L, including the boundary value). Secondary objective: To evaluate the efficacy and safety of WS016 in the initial 2-day treatment of hyperkalemia correction; to evaluate the effect of WS016 on other electrolytes. Part B: Primary objective: To evaluate the long-term safety of WS016 in the extended phase. Secondary objective: To evaluate the long-term effectiveness of WS016 in the extended phase.